Nup210’s role in leukemia and its potential as a target
Official title: Characterizing the functions of Nup210 in leukemia
Funded at Sanford Burnham Prebys Medical Discovery Institute · NIH-11451105 · Data updated 2026-11-12
A doctor-scientist team is studying how a protein called Nup210 helps a type of blood cancer (AML) grow, with the goal of finding new ways to predict outcomes and treat the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sanford Burnham Prebys Medical Discovery Institute NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $803,681 |
| NIH project number | 1R01CA308029-01A1 |
| Project ID | NIH-11451105 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with acute myeloid leukemia, particularly those with aggressive forms, may benefit from future translational advances arising from this work.
✕Less likely to help
Patients without AML or without tumors expressing Nup210 may not directly benefit from these findings.
What this research studies
This project looks at how the nuclear pore protein Nup210 affects leukemia cells, especially in aggressive AML. Researchers will use animal models and cellular assays to understand how Nup210 changes cell behavior and interacts with other molecules. The work aims to connect Nup210’s activity with how leukemia develops and responds to possible treatments. If successful, the findings could reveal new targets for therapy and improve prognosis for patients with AML.
Why it matters
Potential benefit: Understanding Nup210 could lead to new biomarkers and therapeutic targets to help AML patients.
How similar studies have gone: Preliminary data show Nup210 is linked to poor survival and leukemic transformation, supporting potential impact but requires validation in models closer to human disease.
Where this research is happening
-
Sanford Burnham Prebys Medical Discovery Institute
La Jolla, United States Active
Researchers
- Principal investigator: Dangelo, Maximiliano a — Sanford Burnham Prebys Medical Discovery Institute
- Study coordinator: Dangelo, Maximiliano a
Related research
Other NIH-funded projects on the same topics.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Understanding TCRs in Leukemia to Improve Immunotherapies
A short, patient-friendly look at a project trying to map how immune cells recognize leukemia so future therapies can be better and safer for people with AML.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.